Skip to main content

Table 4 Number (%) of study patients reporting AEs (safety population)

From: Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease

Preferred term PBO MDI GP MDI GP MDI GP MDI GP MDI TIO
n = 21 14.4 μg 28.8 μg 57.6 μg 115.2 μg 18 μg
n (%) n = 21 n = 23 n = 21 n = 21 n = 22
   n (%) n (%) n (%) n (%) n (%)
One or more AEs 4 (19.0) 3 (14.3) 3 (13.0) 5 (23.8) 3 (14.3) 4 (18.2)
Dry mouth 2 (9.5) 1 (4.8) 0 3 (14.3) 1 (4.8) 2 (9.1)
Oropharyngeal pain 0 1 (4.8) 0 0 1 (4.8) 0
Bronchospasm paradoxical 0 0 0 0 1 (4.8) 0
Nasopharyngitis 0 0 0 1 (4.8) 0 0
Urinary tract infection 0 0 0 1 (4.8) 0 0
Vessel puncture site hematoma 0 0 1 (4.3) 0 0 1 (4.5)
Sinusitis 0 0 1 (4.3) 0 0 0
Headache 0 0 1 (4.3) 0 0 0
Insomnia 0 0 1 (4.3) 0 0 0
Dyspnea 0 0 1 (4.3) 0 0 0
Hypertension 0 0 1 (4.3) 0 0 0
Dizziness 0 1 (4.8) 0 0 0 0
Cough 0 1 (4.8) 0 0 0 0
Diarrhea 0 0 0 0 0 1 (4.5)
Umbilical hernia 1 (4.8) 0 0 0 0 0
Gastroenteritis 1 (4.8) 0 0 0 0 0
Gastrointestinal viral infection 1 (4.8) 0 0 0 0 0
  1. AE = adverse event; DPI = dry powder inhaler GP MDI=glycopyrronium metered-dose inhaler; PBO = placebo; TIO = tiotropium.